Onpattro, Tegsedi Cardiac Imaging And Serum Biomarker Data Failed To Impress US FDA

 
• By Sue Sutter
  
Drug Review Profile regular column
For both Onpattro and Tegsedi, FDA reviewers recommended limiting the indications to hATTR patients with polyneuropathy.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews